Tarceva Helps OSI To Solid First Quarter
This article was originally published in The Pink Sheet Daily
Data from SATURN, BETA trials – and ASCO – will tell more soon.
You may also be interested in...
The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.